Senior Postdoctoral Researcher
Genomics, Epigenetics and Immunology
The maps of human genetic variation that associate with disease susceptibility allow us to generate and test biological hypotheses. Emerging evidence suggests that causal variants underlying disease susceptibility often function through regulatory effects on the transcription of target genes. However, there are challenges in harnessing of susceptibility loci for drug target identification and therapeutic application, including limitations in (i) exposition of causal variants within susceptibility loci, (ii) understanding of the context specificity, and (iii) mechanistic insights into their influence on cellular behaviours and clinical outcomes.
My current research is focused on identifying and characterising regulatory variants modulating extreme innate immune response phenotypes and the interplay of innate-adaptive immunity in order to gain insights into the causal mechanisms driving heterogeneity of pathogenesis in infectious diseases including sepsis, tuberculosis and COVID19. The research combines bioinformatics, multi-omics approaches and CRISPR-based epigenetic editings to study variants in disease relevant primary tissue/cells and human iPSC-derived models.
Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer.
Wiecek AJ. et al, (2023), Genome biology, 24
Comprehensive epigenomic profiling reveals the extent of disease-specific chromatin states and informs target discovery in ankylosing spondylitis
Brown AC. et al, (2023), Cell Genomics, 100306 - 100306
A transcriptomic approach to understand patient susceptibility to pneumonia after abdominal surgery
Torrance H. et al, (2023)
Epigenomic analysis reveals a dynamic and context-specific macrophage enhancer landscape associated with innate immune activation and tolerance
Zhang P. et al, (2022), Genome Biology, 23
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58